Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

NCT02317549 is registered in ClinicalTrials.gov with Leading BioSciences, Inc as lead sponsor.

NCT NCT02317549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02317549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)
Lead sponsor
Leading BioSciences, Inc
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2015
Completion date
March 31, 2016
Enrollment
8 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock